ACE2 and COVID-19: However, despite clear evidence that ACE2 is the main receptor for COVID-19 (82), several studies have encouraged the continued use of ACE-I and ARB medications in patients with diabetes or circulatory diseases as use of these medications is not associated with severe COVID-19 and may even be beneficial in reducing disease severity in these patients (57, 60, 83, 84).